ANI Pharmaceuticals (NASDAQ:ANIP) Receives “Buy” Rating from Guggenheim

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “buy” rating reissued by investment analysts at Guggenheim in a research note issued to investors on Monday,Benzinga reports. They currently have a $86.00 price objective on the specialty pharmaceutical company’s stock. Guggenheim’s price objective indicates a potential upside of 38.71% from the stock’s current price.

ANIP has been the topic of a number of other reports. StockNews.com downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, April 24th. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price objective on the stock. Jefferies Financial Group began coverage on ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a “buy” rating and a $80.00 price objective on the stock. Truist Financial boosted their price objective on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a research note on Monday, April 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $80.13.

ANI Pharmaceuticals Stock Down 0.5%

Shares of ANIP opened at $62.00 on Monday. The company has a market capitalization of $1.35 billion, a PE ratio of -112.73 and a beta of 0.56. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $77.00. The stock’s 50-day moving average price is $66.93 and its two-hundred day moving average price is $60.74. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.37 by $0.33. The firm had revenue of $197.12 million for the quarter, compared to the consensus estimate of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business’s quarterly revenue was up 43.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.82 EPS. On average, analysts anticipate that ANI Pharmaceuticals will post 3.86 EPS for the current year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the business’s stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the sale, the vice president now directly owns 80,145 shares of the company’s stock, valued at approximately $5,526,799.20. The trade was a 0.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $60.20, for a total value of $60,200.00. Following the sale, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at $4,131,164.80. This represents a 1.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,200 shares of company stock valued at $197,792 in the last three months. Corporate insiders own 11.10% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANIP. Northern Trust Corp grew its holdings in shares of ANI Pharmaceuticals by 6.1% in the first quarter. Northern Trust Corp now owns 216,862 shares of the specialty pharmaceutical company’s stock valued at $14,519,000 after acquiring an additional 12,517 shares in the last quarter. Raymond James Financial Inc. grew its holdings in shares of ANI Pharmaceuticals by 41.4% in the first quarter. Raymond James Financial Inc. now owns 100,164 shares of the specialty pharmaceutical company’s stock valued at $6,706,000 after acquiring an additional 29,338 shares in the last quarter. Aberdeen Group plc grew its holdings in shares of ANI Pharmaceuticals by 76.1% in the first quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock valued at $28,059,000 after acquiring an additional 181,134 shares in the last quarter. Mitsubishi UFJ Asset Management UK Ltd. bought a new position in shares of ANI Pharmaceuticals in the first quarter valued at approximately $335,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of ANI Pharmaceuticals by 32.0% in the first quarter. Russell Investments Group Ltd. now owns 185,475 shares of the specialty pharmaceutical company’s stock valued at $12,418,000 after acquiring an additional 44,979 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.